Patient info Open main menu

Mirapexin 0.35 mg tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
0.35 mg
Contains active substance:

Patient leaflet - Mirapexin 0.35 mg tablets

1. What MIRAPEXIN is and what it is used for

MIRAPEXIN contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

MIRAPEXIN is used to:

  • treat the symptoms of primary Parkinson’s

    disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease).

  • treat the symptoms of moderate to severe

    primary Restless Legs Syndrome in adults.

2. What you need to know before you take MIRAPEXIN

Do not take MIRAPEXIN

  • if you are allergic to pramipexole or to any of

    the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before taking MIRAPEXIN. Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:

  • Kidney disease
  • Hallucinations (seeing, hearing or feeling things

    that are not there). Most hallucinations are visual.

    • Dyskinesia (e.g. abnormal, uncontrolled

      movements of the limbs). If you have advanced Parkinson’s disease and are also taking levodopa, you might develop dyskinesia during the up-titration of MIRAPEXIN.

    • Dystonia (inability of keeping your body and neck

      straight and upright (axial dystonia)). In particular, you may experience forward flexion of the head and neck (also called antecollis), forward bending of the lower back (also called camptocormia) or sidewards bending of the back (also called pleurothotonus or Pisa Syndrome).

    • Sleepiness and episodes of suddenly falling asleep
    • Psychosis (e.g. comparable with symptoms of

      schizophrenia)

    • Vision impairment. You should have regular eye

      examinations during treatment with MIRAPEXIN.

    • Severe heart or blood vessels disease. You will

      need to have your blood pressure checked regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).

    • Restless legs augmentation syndrome. If you

      experience that symptoms start earlier than usual in the evening (or even the afternoon), are more intense or involve larger parts of the affected limbs or involve other limbs. Your doctor may lower your dose or stop the treatment.

Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.

Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality). Your doctor may need to adjust or stop your dose.

Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your MIRAPEXIN treatment. If the problems persist more than a few weeks, your doctor may need to adjust your treatment.

Tell your doctor if you are developing an inability of keeping your body and neck straight and upright (axial dystonia). If this happens, your doctor may want to adjust or change your medication.

Children and adolescents

MIRAPEXIN is not recommended for use in children or adolescents under 18 years.

Other medicines and MIRAPEXIN

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines, herbal remedies, health foods or supplements that you have obtained without a prescription.

You should avoid taking MIRAPEXIN together with antipsychotic medicines.

Take care if you are taking the following medicines:

  • cimetidine (to treat excess stomach acid and

    stomach ulcers)

  • amantadine (which can be used to treat

    Parkinson’s disease)

  • mexiletine (to treat irregular heartbeats,

    a condition known as ventricular arrhythmia)

  • zidovudine (which can be used to treat the

    acquired immune deficiency syndrome (AIDS), a disease of the human immune system)

  • cisplatin (to treat various types of cancers)
  • quinine (which can be used for the prevention

    of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria))

  • procainamide (to treat irregular heart beat)

If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with MIRAPEXIN.

Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases MIRAPEXIN may affect your ability to drive and operate machinery.

MIRAPEXIN with food, drink and alcohol

You should be cautious while drinking alcohol during treatment with MIRAPEXIN.

MIRAPEXIN can be taken with or without food.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will then discuss with you if you should continue to take MIRAPEXIN.

The effect of MIRAPEXIN on the unborn child is not known. Therefore, do not take MIRAPEXIN if you are pregnant unless your doctor tells you to do so.

MIRAPEXIN should not be used during breast-feeding. MIRAPEXIN can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of MIRAPEXIN is unavoidable, breast-feeding should be stopped.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

MIRAPEXIN can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.

MIRAPEXIN has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s disease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.

3. How to take MIRAPEXIN

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The doctor will advise you on the right dosing.

You can take MIRAPEXIN with or without food. Swallow the tablets with water.

Parkinson’s disease

The daily dose is to be taken divided into 3 equal doses.

During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg three times a day (equivalent to 0.264 mg daily):

1st week
Number of tablets1 tablet MIRAPEXIN 0.088 mg three times a day
Total daily dose (mg)0.264

This will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

2nd week3rd week
Number of tablets

1 tablet

MIRAPEXIN 0.18 mg three times a day

OR

2 tablets

MIRAPEXIN 0.088 mg three times a day

1 tablet

MIRAPEXIN 0.35 mg three times a day OR

2 tablets

MIRAPEXIN 0.18 mg three times a day

Total daily dose (mg)0.541.1

The usual maintenance dose is 1.1 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of pramipexole a day. A lower maintenance dose of three MIRAPEXIN 0.088 mg tablets a day is also possible.

Lowest

maintenance dose

Highest

maintenance dose

Number of tablets

1 tablet

MIRAPEXIN 0.088 mg three times a day

1 tablet

MIRAPEXIN 0.7 mg and 1 tablet

MIRAPEXIN 0.35 mg three times a day

Total daily dose (mg)0.2643.15

Patients with kidney disease

If you have moderate or severe kidney disease, your doctor will prescribe a lower dose. In this case, you will have to take the tablets only once or twice a day. If you have moderate kidney disease, the usual starting dose is 1 tablet MIRAPEXIN 0.088 mg twice a day. In severe kidney disease, the usual starting dose is just 1 tablet MIRAPEXIN 0.088 mg a day.

Restless Legs Syndrome

The dose is usually taken once a day, in the evening, 2-3 hours before bedtime.

During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg once a day (equivalent to 0.088 mg daily):

1st week

Number of tablets

1 tablet

MIRAPEXIN 0.088 mg

Total daily dose (mg)0.088

This will be increased every 4-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

2nd week3rd week4th week
Number of tablets

1 tablet

MIRAPEXIN 0.18 mg

OR

2 tablets

MIRAPEXIN 0.088 mg

1 tablet

MIRAPEXIN 0.35 mg

OR

2 tablets

MIRAPEXIN 0.18 mg

OR

4 tablets

MIRAPEXIN 0.088 mg

1 tablet

MIRAPEXIN 0.35 mg

and 1 tablet MIRAPEXIN 0.18 mg

OR

3 tablets

MIRAPEXIN 0.18 mg

OR

6 tablets

MIRAPEXIN 0.088 mg

Total daily dose (mg)0.180.350.54

The daily dose should not exceed 6 tablets MIRAPEXIN 0.088 mg or a dose of 0.54 mg (0.75 mg pramipexole salt).

If you stop taking your tablets for more than a few days and want to restart the treatment, you must start again at the lowest dose. You can then build up the dose again, as you did the first time. Ask your doctor for advice.

Your doctor will review your treatment after 3 months to decide whether or not to continue the treatment.

Patients with kidney disease

If you have severe kidney disease, MIRAPEXIN may not be a suitable treatment for you.

If you take more MIRAPEXIN than you should

If you accidentally take too many tablets,

  • Contact your doctor or nearest hospital casualty department immediately for advice.
  • You may experience vomiting, restlessness, or any of the side effects as described in section 4 “Possible side effects”.

If you forget to take MIRAPEXIN

Do not worry. Simply leave out that dose completely and then take your next dose at the right time. Do not try to make up for the missed dose.

If you stop taking MIRAPEXIN

Do not stop taking MIRAPEXIN without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.

If you suffer from Parkinson’s disease you should not stop treatment with MIRAPEXIN abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:

  • akinesia (loss of muscle movement)
  • rigid muscles
  • fever
  • unstable blood pressure
  • tachycardia (increased heart rate)
  • confusion
  • depressed level of consciousness (e.g. coma)

If you stop or reduce MIRAPEXIN you may also develop a medical condition called dopamine agonist withdrawal syndrome. The symptoms include depression, apathy, anxiety, fatigue, sweating or pain. If you experience these symptoms you should contact your physician.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist. Package leaflet: Information for the user

MIRAPEXIN® 0.088 mg tablets MIRAPEXIN® 0.18 mg tablets MIRAPEXIN® 0.35 mg tablets MIRAPEXIN® 0.7 mg tablets

pramipexole

abcd

MIRAPEXIN® 0.088 mg tablets MIRAPEXIN® 0.18 mg tablets MIRAPEXIN® 0.35 mg tablets MIRAPEXIN® 0.7 mg tablets pramipexole

abcd

MIRAPEXIN® 0.088 mg tablets

MIRAPEXIN® 0.18 mg tablets

MIRAPEXIN® 0.35 mg tablets

MIRAPEXIN® 0.7 mg tablets

pramipexole

abcd

File information
Issue date of TD:

Perigord No: 803120 P1

Mandatory in
TDPrintfile
12.08.2021YesYes
PPM SKU: P053706NoYes
PPM SKU version: 004NoYes
NoYes
Print colors: PAN BLACKNoYes
Mat. No. Pack. Site: 319165-04NoYes
Additional Requirements of Packaging site
Template name: TD-PI_595x270_85x55Index: 2.0

Example:

Only for BI-internal use, Template according to Drawing no.: SP-14-0053-001-B_Index_g

In-process control code specification

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Evaluation of these side effects is based on the following frequencies:

Very commonmay affect more than 1 in 10 people
Commonmay affect up to 1 in 10 people
Uncommonmay affect up to 1 in 100 people
Raremay affect up to 1 in 1 000 people
Very raremay affect up to 1 in 10 000 people
Not knownFrequency cannot be estimated from the available data

If you suffer from Parkinson’s disease, you may experience the following side effects:

Very common:

  • Dyskinesia (e.g. abnormal, uncontrolled

    movements of the limbs)

  • Sleepiness
  • Dizziness
  • Nausea (sickness)

Common:

  • Urge to behave in an unusual way
  • Hallucinations (seeing, hearing or feeling things

    that are not there)

  • Confusion
  • Tiredness (fatigue)
  • Sleeplessness (insomnia)
  • Excess of fluid, usually in the legs (peripheral

    oedema)

  • Headache
  • Hypotension (low blood pressure)
  • Abnormal dreams
  • Constipation
  • Visual impairment
  • Vomiting (being sick)
  • Weight loss including decreased appetite

Uncommon:

  • Paranoia (e.g. excessive fear for one’s own

    well-being)

  • Delusion
  • Excessive daytime sleepiness and suddenly

    falling asleep

  • Amnesia (memory disturbance)
  • Hyperkinesia (increased movements and inability

    to keep still)

  • Weight increase
  • Allergic reactions (e.g. rash, itching, hypersensitivity)
  • Fainting
  • Cardiac failure (heart problems which can cause

    shortness of breath or ankle swelling)*

  • Inappropriate antidiuretic hormone secretion*
  • Restlessness
  • Dyspnoea (difficulties to breathe)
  • Hiccups
  • Pneumonia (infection of the lungs)

    • Inability to resist the impulse, drive or

      temptation to perform an action that could be harmful to you or others, which may include:

      • Strong impulse to gamble excessively despite

        serious personal or family consequences.

      • Altered or increased sexual interest and

        behaviour of significant concern to you or to others, for example, an increased sexual drive.

      • Uncontrollable excessive shopping or spending
      • Binge eating (eating large amounts of food

        in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*

    • Delirium (decreased awareness, confusion,

      loss of reality)

Rare:

  • Mania (agitation, feeling elated or over-excited)
  • Spontaneous penile erection

Not known:

  • After stopping or reducing your MIRAPEXIN

    treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviours; he will discuss ways of managing or reducing the symptoms.

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2 762 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

If you suffer from Restless Legs Syndrome, you may experience the following side effects:

Very common:

  • Nausea (sickness)
  • Symptoms that start earlier than usual, are more

    intense or involve other limbs (Restless legs augmentation syndrome).

Common:

  • Changes in sleep pattern, such as sleeplessness

    (insomnia) and sleepiness

  • Tiredness (fatigue)
  • Headache
  • Abnormal dreams
  • Constipation
  • Dizziness
  • Vomiting (being sick)

Uncommon:

  • Urge to behave in an unusual way*
  • Cardiac failure (heart problems which can cause

    shortness of breath or ankle swelling)*

  • Inappropriate antidiuretic hormone secretion*
  • Dyskinesia (e.g. abnormal, uncontrolled

    movements of the limbs)

  • Hyperkinesia (increased movements and inability

    to keep still)*

    • Paranoia (e.g. excessive fear for one’s own well-being)*
    • Delusion*
    • Amnesia (memory disturbance)*
    • Hallucinations (seeing, hearing or feeling things

      that are not there)

    • Confusion
    • Excessive daytime sleepiness and suddenly

      falling asleep

    • Weight increase
    • Hypotension (low blood pressure)
    • Excess of fluid, usually in the legs

      (peripheral oedema)

    • Allergic reactions (e.g. rash, itching, hypersensitivity)
    • Fainting
    • Restlessness
    • Visual impairment
    • Weight loss including decreased appetite
    • Dyspnoea (difficulties to breathe)
    • Hiccups
    • Pneumonia (infection of the lungs)*
    • Inability to resist the impulse, drive or

      temptation to perform an action that could be harmful to you or others, which may include:

      • Strong impulse to gamble excessively despite

        serious personal or family consequences.*

      • Altered or increased sexual interest and

        behaviour of significant concern to you or to others, for example, an increased sexual drive.*

      • Uncontrollable excessive shopping or spending*
      • Binge eating (eating large amounts of food

        in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)*

    • Mania (agitation, feeling elated or over-excited)*
    • Delirium (decreased awareness, confusion, loss

      of reality)*

Rare:

  • Spontaneous penile erection

Not known:

  • After stopping or reducing your MIRAPEXIN

    treatment: Depression, apathy, anxiety, fatigue, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS).

Tell your doctor if you experience any of these behaviours; he will discuss ways of managing or reducing the symptoms.

For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 1 395 patients treated with pramipexole. The frequency category is probably not greater than “uncommon”.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

5. How to store MIRAPEXIN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Do not store above 30 °C.

Store in the original package to protect the tablets from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What MIRAPEXIN contains

The active substance is pramipexole.

Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.

The other ingredients are mannitol, maize starch, anhydrous colloidal silica, povidone K 25 and magnesium stearate.

What MIRAPEXIN looks like and contents of the pack

MIRAPEXIN 0.088 mg tablets are white, of round shape, flat, and without scoring.

MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat. Tablets are scored on both sides and breakable in halves.

MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat. Tablets are scored on both sides and breakable in halves.

All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P6, P7, P8, or P9 on the other side, representing the tablet strengths 0.088 mg, 0.18 mg, 0.35 mg, and 0.7 mg, respectively.

All strengths of MIRAPEXIN are available in aluminium blister strips of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.

Marketing Authorisation Holder

Boehringer Ingelheim International GmbH Binger Strasse 173

55216 Ingelheim am Rhein

Germany

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173

55216 Ingelheim am Rhein

Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom

Boehringer Ingelheim Ltd.

Tel: +44 1344 424 600

This leaflet was last revised in 04/2024.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 14598/0207

Last revision stated in the text: April 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Mirapexin 0.35 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Pramipexole
Strength 0.35 mg
Pharmaceutical form Oral tablet
The tablets are white, flat, of oval shape, scored on both sides, and have a code embossed (one side with the code P8, and one side with the Boehringer Ingelheim company symbol).
Tablets can be divided into equal halves.
How is it taken Oral
Excipients Mannitol, Maize starch, Anhydrous colloidal silica, Povidone K 25, Magnesium stearate
Pack sizes 30 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage Do not store above 30 °C.
Store in the original package in order to protect from light.
Drug group (ATC) Anti-Parkinson drugs, dopamine agonists
  1. N Nervous system drugs
    1. N04 Anti-parkinson drugs
      1. N04B Dopaminergic agents
        1. N04BC Dopamine agonists
          1. N04BC05 pramipexole
Marketing authorisation PLGB 14598/0207 (first authorised 1 January 2021)
Marketing authorisation holder Boehringer Ingelheim International GmbH
Codes GTIN 5012816099630 · BNF 04090100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.